This guideline covers the care and treatment of people aged 18 and over with generalised anxiety disorder (chronic anxiety) or panic disorder (with or without agoraphobia or panic attacks). It aims to help people achieve complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.
In July 2019, we updated footnotes and tables in this guideline to reflect a change in the law relating to pregabalin and gabapentin. As of 1 April 2019, because of a risk of abuse and dependence pregabalin and gabapentin are controlled under the Misuse of Drugs Act 1971 as class C substances and scheduled under the Misuse of Drugs Regulations 2001 as schedule 3.
This guideline includes recommendations on:
We checked this guideline in March 2020. We found no new evidence that affects the recommendations of this guideline.
This guideline was previously called generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: management in primary, secondary and community care.
This guideline updates and replaces NICE guideline CG22 (December 2004).